<DOC>
	<DOC>NCT00810706</DOC>
	<brief_summary>The ATENA phase III randomized parallel-group multicenter trial is designed to compare 5 years of adjuvant exemestane versus 5 years of observation in postmenopausal women with operable breast cancer who have received 5-7 years of adjuvant tamoxifen. The primary endpoint for the core protocol is disease-free survival (DFS). Exemestane treatment is planned for 5 years unless disease relapse or excessive toxicity is documented, the patient refuses further treatment or any new anti-cancer therapy is initiated.</brief_summary>
	<brief_title>Adjuvant Post-Tamoxifen Exemestane Trial</brief_title>
	<detailed_description>- Patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry. - A substudy (ATENA lipid substudy)is designed to evaluate changes in the patients' serum lipid profile during study treatment.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal women only histologically confirmed stage IIIIA primary adenocarcinoma of the breast estrogen and/or progesterone receptors positive or unknown patients should have undergone surgery with a curative intent patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry Absence of any evidence of local or distant metastatic disease was required prior to randomization DCIS, bilateral breast cancer, evidence of metastasis, ER and Pgr negative</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Aromatase inhibitors</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Lipids</keyword>
</DOC>